Nemaura Pharma has been recognised for its excellence in innovation by the European Eurostars program having successfully secured a £0.25m grant award for its unique MAP (microarray-patch) platform technology. The award was received in conjunction with a partner company in the Netherlands whereby the project aims to produce a mass scale manufacture process using a large area maskless fabrication approach.
The EUREKA Eurostars grant is a funding program that supports research and development (R&D) projects undertaken by small and medium-sized enterprises (SMEs) in Europe. It is a joint initiative of EUREKA, a pan-European intergovernmental network that promotes collaborative R&D, and the European Union (EU) funding program Horizon 2020. The EUREKA Eurostars grant is a highly competitive funding program for SMEs in Europe with multiple SMEs across Europe vying for limited funding opportunities.
Nemaura’s MAP technology is one that is expected to be available at very low cost once the commercial manufacture process has been developed and has the potential tobe adopted with a large range of vaccines and therapeutics.
Dr Chowdhury, CEO of Nemaura said: “We are delighted to have been awarded this highly competitive grant which we believe is a huge endorsement of both the innovative nature of our platform technology as well as the massive potential for future vaccine and drug delivery.”
Business Development enquiries:
bd@nemaura.co.uk
About Nemaura Pharma
www.nemaura.co.uk
Founded in 2005, Nemaura Pharma is a private specialist biotech company with headquarters and research facilities in the Advanced Technology Centre on the Loughborough University Science and Enterprise Park (LUSEP) in the United Kingdom.
The company employs multi-disciplinary teams of scientists and engineers working in innovative drug formulation and medical device technologies designed to radically improve the way drugs are administered through the skin. It has patents secured or pending in multiple countries across numerous patent families.